30  Inorganic pharmaceuticals

Blower, Philip J.

doi:10.1039/b312109g

Cited by 27 publications

(21 citation statements)

References 432 publications

(228 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has well been established that organotin(IV) compounds are very important in cancer chemotherapy because of their apoptotic inducing character [14][15][16], while during the last few year it is noticeable that organotin compounds occupy an important place in cancer chemotherapy reports [14]. Recently, Blower described thirty interesting inorganic pharmaceuticals, four of which are tin compounds [17]. Despite this, the exact mechanism of anti-tumor action of organotin compounds remains unknown.…”

Section: Introductionmentioning

confidence: 98%

Antiproliferative and anti-tumor activity of organotin compounds

Hadjikakou

Hadjiliadis

2009

Coordination Chemistry Reviews

391

255

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Antiproliferative and anti-tumor activity of organotin compounds

Hadjikakou

Hadjiliadis

2009

Coordination Chemistry Reviews

391

255

View full text Add to dashboard Cite

“…The design of improved organotin(IV) antitumour agents occupies a significant place in cancer chemotherapy, as revealed from their remarkable therapeutic potential reflected in recent research reports [1][2][3][4][5][6][7][8][9][10][11][12]. Consequently, a large number of organotin(IV) carboxylates have been investigated for their antitumour potential owing to their better hydrolytic stability compared to organotin(IV) halides.…”

Section: Introductionmentioning

confidence: 99%

Triphenyltin(IV) 2-[(E)-2-(aryl)-1-diazenyl]benzoates as anticancer drugs: synthesis, structural characterization, in vitro cytotoxicity and study of its influence towards the mechanistic role of some key enzymes

et al. 2009

View full text Add to dashboard Cite

Triphenyltin(IV) complexes of composition [Ph(3)SnL(1)H](n) (1) and [Ph(3)SnL(2)H](n) (2) (where L(1)H = 2-[(E)-2-(3-formyl-4-hydroxyphenyl)-1-diazenyl]benzoate and L(2)H = 2-[(E)-2-(4-Hydroxy-5-methylphenyl)-1-diazenyl]benzoate) were synthesized and characterized by spectroscopic ((1)H, (13)C and (119)Sn NMR, IR, (119)Sn Mössbauer) techniques in combination with elemental analysis. The molecular structures and geometries of the complexes (1 and 2) were fully optimized using the quantum mechanical method (PM3). Complexes (1 and 2) were found to exhibit stronger cytotoxic activity in vitro across a panel of human tumour cell lines viz., A498, EVSA-T, H226, IGROV, M19 MEL, MCF-7 and WIDR. The test compounds 1 and 2 exhibit comparable results and both the compounds are found to be far superior to CCDP (cisplatin), 5-FU (5-fluorouracil) and ETO (etoposide) across a panel of cell lines and the activity is more pronounced for the A498 (22 fold) and H226 (33 fold) cell lines compared to CCDP, and A498 (13 fold), H226 (39 fold) and MCF-7 (33 fold) cell lines compared to ETO. The test compounds are even 23 fold more active in magnitude in terms of the ID(50) value at least against the H226 cell lines when compared with MTX (methotrexate). Further, the mechanistic role of cytotoxic activity of test compounds (1 and 2), are discussed in relations to the theoretical results of docking studies with some of the key enzymes such as ribonucleotide reductase, thymidylate synthase, thymidylate phosphorylase and topoisomerase II.

show abstract

“…Additionally, more organotin(IV) compounds have undergone testing as potential anticancer agents than any other single group of compounds [29,30]. The design of improved organotin(IV) antitumour agents occupies a significant place in cancer chemotherapy, as revealed from their remarkable therapeutic potential reflected in recent research reports [31][32][33][34][35][36][37][38][39][40][41].…”

Section: Introductionmentioning

confidence: 99%

In vitro cytotoxic evaluation of novel dichlorodiorgano[N-(2-pyridylmethylene)arylamine]tin(IV) derivatives in human tumor cell lines

Baul

Vos²

2009

Invest New Drugs

View full text Add to dashboard Cite

The present report overviews the studies on diorganotin(IV) complexes of N-(2-pyridylmethylene)arylamine, R(2)SnCl(2).L (R = Me (1), Et (2), Bu (3) or Ph (4)) as cytotoxic agents. This family of complexes was designed to include highly electron-donating N;Nchelating ligand to afford octahedral R(2)SnCl(2).L complexes of relatively high hydrolytic stability, with the aim to retain ligand binding throughout the biological activity for achieving controlled processes and allowing mechanistic evaluation. It is observed that the high cytotoxic activity is dependent on the Sn-R groups and Sn-N bond lengths, and which is related to the cytotoxic potential. Complex (2) was found to exhibit stronger cytotoxic activity in vitro particularly for A498 (renal cancer), IGROV (ovarian cancer), MCF-7 (breast cancer), and WIDR (colon cancer) of human tumour cell lines and the results are far superior to standard reference drugs e.g., doxorubicin, cisplatin, 5-fluorouracil, methotrexate, etoposide including paclitaxel. The important insights gained with the diorganotin(IV) compounds in regards to their cytotoxic activity are discussed.

show abstract

30 Inorganic pharmaceuticals

Cited by 27 publications

References 432 publications

Antiproliferative and anti-tumor activity of organotin compounds

Antiproliferative and anti-tumor activity of organotin compounds

Triphenyltin(IV) 2-[(E)-2-(aryl)-1-diazenyl]benzoates as anticancer drugs: synthesis, structural characterization, in vitro cytotoxicity and study of its influence towards the mechanistic role of some key enzymes

In vitro cytotoxic evaluation of novel dichlorodiorgano[N-(2-pyridylmethylene)arylamine]tin(IV) derivatives in human tumor cell lines

Contact Info

Product

Resources

About